Novo Nordisk admits no liability or wrongdoing but will pay investors $100m to “avoid the burden, inherent risk and expense of further litigation”
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.